Adrafinil
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Adrafinil (2-benzhydrylsulfinyl-N-hydroxyacetamide) is a synthetic eugeroic of the benzhydrylsulfinylacetamide class. It is a prodrug of modafinil, converted to its active form in the liver. Adrafinil's effects are mediated by DAT blockade, producing wakefulness through increased extracellular dopamine.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Identified in 1974 at Laboratoire Louis Lafon in France, adrafinil was launched commercially as Olmifon in 1985 for narcolepsy and age-related vigilance deficits.[2] The manufacturer voluntarily discontinued it in 2011, citing an unfavorable risk–benefit ratio relative to modafinil.[3] It now circulates as an unregulated nootropic supplement in several jurisdictions.[4]
Subjective effects include sustained wakefulness, cognitive clarity, mood elevation, and increased motivation. The experience is one of quiet alertness — a gradual, clean arousal without the jittery push or euphoria characteristic of amphetamine-class stimulants.[5] Insomnia, headache, nausea, and mild anxiety are common unsought effects.[6]
Dependence liability is minimal, and acute toxicity is low in animal models.[7][5] The principal chronic concern is hepatic — adrafinil requires additional liver processing compared to modafinil, and one case of persistent involuntary facial movements has been reported after chronic use.[8] No dedicated clinical trials exist for adrafinil; the evidence base rests almost entirely on modafinil research and the assumption of equivalence after conversion.[9]
History[edit]
Discovery
Adrafinil (CRL-40028) was identified in 1974 by researchers at Laboratoire Louis Lafon in France during systematic investigation of benzhydryl sulfoxide compounds.[2] Two years later, modafinil was recognized as adrafinil's primary active metabolite.[10] Michel Jouvet, the French neurologist who discovered REM sleep, began prescribing adrafinil to narcoleptic patients around 1977–1978, but results were inconsistent; by 1983 he had shifted to prescribing modafinil directly.[2]
Clinical and commercial history
Adrafinil launched in France on 19 September 1985 under the brand name Olmifon, indicated for narcolepsy and vigilance deficits in the elderly.[2][3] Modafinil received French registration in 1992 and proved clinically superior — direct bioavailability eliminated the need for hepatic prodrug conversion. Cephalon Inc. acquired Lafon in 2001[2] and voluntarily discontinued Olmifon in September 2011, citing an unfavorable risk–benefit ratio.[3]
Modern era
Following discontinuation, adrafinil re-emerged in the nootropic supplement market, particularly in jurisdictions where it remains unregulated.[4] Analytical studies have confirmed its presence in products marketed as dietary supplements in the United States.[4] The compound occupies a regulatory paradox: a discontinued pharmaceutical circulating as an unscheduled supplement while its active metabolite remains a controlled or prescription substance in most of the developed world.[11]
The class name "eugeroic" — from the Greek eu (good) and gregor (wakening) — was coined to describe this new category of wakefulness-promoting agents, of which adrafinil is a founding member.[12] Both adrafinil and modafinil were banned in competitive sport by the World Anti-Doping Agency in 2004 under category S6 (Stimulants), prohibited in-competition only.[13][14]
Chemistry[edit]
Structural class
Adrafinil belongs to the benzhydrylsulfinylacetamide family — a group of compounds built around a diphenylmethane (benzhydryl) core linked to a sulfinyl group. What distinguishes adrafinil from its active metabolite modafinil is a hydroxamic acid (N-hydroxyacetamide) group where modafinil carries a simple acetamide. This hydroxamic acid group is cleaved during liver metabolism, yielding modafinil and the inactive byproduct modafinilic acid.[6][15]
Both adrafinil and modafinil emerged from systematic investigation of benzhydryl sulfoxide compounds at Laboratoire Louis Lafon during the 1970s.[2]
Molecular identity
| Molecular formula | C₁₅H₁₅NO₃S |
| Molecular weight | 289.35 g/mol |
The molecule consists of a diphenylmethane group connected through a sulfinyl bridge (S=O) to an N-hydroxyacetamide chain. The sulfinyl group links the lipophilic benzhydryl portion to the polar hydroxamic acid end.[16][17]
Stereochemistry
The sulfur atom of the sulfinyl group is a chirality center, giving adrafinil two mirror-image forms (enantiomers). The compound is used as a racemic mixture containing both.[18][19]
Whether the two enantiomers differ in pharmacological activity is unknown — a notable gap, given that modafinil's R-enantiomer (armodafinil) has a longer half-life and has been developed as a separate pharmaceutical product.[20]
Physical properties
Adrafinil is a white crystalline solid with limited water solubility. Published melting points conflict between vendor sources (140–142°C vs 159–160°C), and no primary analytical study has resolved the discrepancy.[7] NMR characterization has been published,[21][22] but most physical property data derive from chemical suppliers rather than peer-reviewed sources.
Pharmacology[edit]
Mechanism of action
Adrafinil is pharmacologically inactive or weakly active on its own — it functions as a prodrug, requiring liver conversion to modafinil before producing its primary effects.[6][15]
The parent compound has been classified as an alpha-1 adrenergic receptor agonist based on early pharmacological work showing that adrafinil could not antagonize yohimbine-induced toxicity in mice.[17][23] This classification remains a working hypothesis — no binding affinity data for adrafinil at any receptor have been published, and reviews have acknowledged that adrafinil's direct mechanisms "are still unknown".[12][24]
Once converted, modafinil promotes wakefulness primarily through DAT (DAT) blockade. PET imaging in healthy humans shows that modafinil at 200–400 mg occupies 47–70% of DAT in the caudate, putamen, and nucleus accumbens, increasing extracellular dopamine.[1] Wake-promoting potency correlates with DAT affinity rather than NET affinity.[25]
Unlike amphetamine-class stimulants, modafinil does not cause direct monoamine release — its mechanism is reuptake blockade only, which accounts for its lower reinforcement potential.[5][26] Secondary effects include activation of orexin/hypocretin, histamine, and norepinephrine pathways, along with increased glutamate and decreased GABA in cortical regions.[6][27][5]
Pharmacokinetics
Adrafinil is converted in the liver to modafinil (active) and modafinilic acid (inactive).[6][15] A human self-administration study confirmed this conversion: after a single 200 mg oral dose, both adrafinil and modafinil were detectable in hair at 10 days.[15]
No human pharmacokinetic parameters — peak concentration, bioavailability, or half-life — have been published for adrafinil as parent compound. All human data derive from modafinil studies.[20]
Modafinil reaches peak plasma levels 2–4 hours after oral dosing, with an elimination half-life of approximately 12–15 hours. Steady state is achieved within 2–4 days of repeated dosing. It is approximately 60% protein-bound and primarily eliminated through the kidneys, with less than 10% excreted unchanged.[20] Elimination is slowed in liver impairment, kidney impairment, and elderly patients.[20]
For adrafinil specifically, onset is delayed and peak modafinil concentrations may be lower than with direct modafinil dosing due to the conversion step.
Neuroscience[edit]
Where it acts
Adrafinil's wakefulness-promoting effects, mediated through modafinil, arise from dopaminergic activation in specific arousal circuits. The ventral tegmental area projections to the prefrontal cortex and the ventral periaqueductal gray dopaminergic neurons are key substrates for wake promotion.[26] Modafinil preferentially engages these cortical arousal pathways rather than producing robust reward signaling in the nucleus accumbens — a selectivity that accounts for its lower abuse liability compared to amphetamines.[26]
Beyond dopamine, modafinil recruits orexin/hypocretin neurons in the lateral hypothalamus, histaminergic neurons in the tuberomammillary nucleus, and noradrenergic neurons in the locus coeruleus.[27][5] This multi-system engagement produces sustained alertness without the sympathetic overdrive characteristic of pure dopaminergic stimulants.
Why it matters
Modafinil's pharmacological profile offers a natural test of the distinction between "wanting" (incentive salience, driven by mesolimbic dopamine) and "liking" (hedonic impact). DAT blockade elevates dopamine in the nucleus accumbens, yet the magnitude and kinetics are insufficient to generate strong euphoria or hedonic reinforcement.[26][5] This dissociation — wakefulness and motivation without proportional pleasure — makes adrafinil/modafinil an informative case for understanding how arousal and reward can be pharmacologically separated.
Several fundamental questions remain unanswered. Whether adrafinil has pharmacological activity independent of its conversion to modafinil is unknown — the alpha-1 adrenergic classification suggests direct effects, but no binding data exist. The long-term neural consequences of chronic use are uncharacterized; one case of persistent involuntary facial movement[8] implicates dopaminergic sensitization, but no systematic studies have followed.
Subjective Effects[edit]
Adrafinil's experiential character is shaped by its prodrug nature: the onset unfolds gradually as hepatic conversion to modafinil proceeds, producing a slow-building wakefulness rather than abrupt stimulation. The quality of arousal is characteristically clean — sustained alertness without prominent euphoria, sympathetic drive, or psychomotor agitation. Individual variation is substantial, governed by liver enzyme activity, prior stimulant tolerance, sleep debt, and concurrent medications.
Relative to Modafinil, the experience is qualitatively identical but temporally delayed and potentially attenuated due to incomplete first-pass conversion. Compared to amphetamine-class stimulants, adrafinil produces notably less euphoria and less anxiety at equivalent wake-promoting doses, consistent with modafinil's reuptake-blockade-only mechanism.[5][26]
Effect Grid
Sustained wakefulness for 4–6 hours with clear focus enhancement and motivation. Cognitive clarity is the dominant quality — tasks feel easier to initiate and maintain. Memory updating shows the most consistent improvement based on modafinil meta-analytic data (SMD = 0.28). Thought acceleration may be subtly present. The experience resembles a productive, unremarkable state of heightened alertness rather than overt stimulation.
Mild appetite suppression is typical. Headache occurs in a substantial minority (up to 34% in modafinil clinical trials). Nausea is possible. Slight elevation in heart rate may be noticed by sensitive individuals. Dehydration sensation is occasionally reported.
Total duration is approximately 6–10 hours. Sleep disruption is likely if dosed in the afternoon. The slow onset means planning around the 1–2 hour conversion delay is important for timing peak effects with demanding work.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Appetite suppression · Pupil dilation · Nausea · Dry mouth · Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Heart rate perception changes · Restlessness · Dizziness · Dehydration sensation · Vomiting
Information processing enhancement · Thought organization
Timeline
Gradual awareness of increasing alertness as hepatic conversion to modafinil begins. Effects are subtle — drowsiness lifts slowly rather than stimulation arriving. Most users notice little during this phase under rested conditions.
Progressive sharpening of focus and wakefulness as modafinil plasma levels rise. Mental clarity increases noticeably. The transition is smooth — there is no abrupt gear-shift characteristic of direct-acting stimulants.
Sustained plateau of wakefulness and cognitive clarity. Focus enhancement and motivation are most prominent. The quality is characteristically clean — alertness without agitation or euphoria.
Gradual reduction in stimulation without a sharp crash. Wakefulness fades smoothly as modafinil plasma levels decline. Concentration returns to near-baseline.
Residual mild alertness or difficulty initiating sleep. Lingering appetite suppression is occasionally reported. Some users experience subtle cognitive clarity persisting below the threshold of active stimulation.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- slow
- Tolerance reset
- 10.5 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- modafinil · armodafinil · benzhydryl class nootropics
Toxicity
Acute toxicity is low. The mouse oral LD₅₀ is 1,950 mg/kg.[7] No human overdose case reports have been published.
Common adverse effects (derived from modafinil clinical data) include headache (up to 34% in trials), nausea, nervousness, insomnia, diarrhea, dry mouth, and elevated blood pressure and heart rate.[6]
Heart and circulation
Adrafinil and modafinil show lower cardiovascular stimulant risk than cocaine, desipramine, and bupropion at equivalent doses in animal models.[28] Elevated heart rate and blood pressure are nonetheless documented at clinical doses of modafinil.[6]
Liver
Modafinil is rated "unlikely cause of clinically apparent liver injury" by LiverTox. In a US study of 899 drug-induced liver injury cases, none were attributed to modafinil. Liver enzyme elevations exceeding three times the upper limit of normal occurred in less than 1% of patients in safety trials.[9]
No primary literature documents adrafinil-specific liver injury. However, adrafinil requires additional hepatic processing compared to taking modafinil directly, raising a theoretical concern for greater liver burden with chronic use. Liver enzyme monitoring is recommended for chronic adrafinil use.safety citation needed
Movement disorders
A single case report documents persistent involuntary facial movements (orofacial dyskinesia) following chronic adrafinil use. The movements did not resolve after four months of discontinuation and required treatment with tetrabenazine, a dopamine-depleting drug.[8] Neurologically vulnerable patients — including elderly and post-stroke individuals — appear at higher risk for movement-related adverse effects.citation needed
Skin reactions
Rare severe skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with modafinil, more commonly in children.[9]
Psychological risks
Anxiety and nervousness are documented adverse effects of modafinil, particularly at higher doses.[6] A systematic review found no preponderance of adverse mood changes when modafinil was used for cognitive enhancement in healthy subjects.[29]
Modafinil carries caution for individuals with a history of psychosis or mania, given its dopaminergic and adrenergic stimulation. No psychiatric case reports specific to adrafinil have been identified.inferred
Tolerance and dependence
Tolerance develops with prolonged use. No controlled human studies have characterized its rate for adrafinil specifically. The mechanism is presumed to involve dopamine receptor changes secondary to sustained DAT occupancy.[1] Cross-tolerance is confirmed with modafinil and armodafinil.
Physical dependence is rare. Few confirmed cases of modafinil dependence appear in the published literature.[5] Psychological dependence is possible, but modafinil does not sustain robust self-administration in animal models.[5]
The lower abuse liability relative to amphetamines is attributed to slower DAT occupancy kinetics, absence of direct monoamine release, and selective arousal without robust reward signaling.[5][26]
No controlled withdrawal studies exist. Fatigue rebound effect following cessation of chronic use has been reported anecdotally. No severe withdrawal syndrome has been documented.citation needed
Drug interactions
Adrafinil's interaction profile is mediated through modafinil.
The most critical interaction involves CYP3A4 induction. Modafinil induces CYP3A4, reducing the effectiveness of drugs processed by this enzyme. This includes hormonal contraceptives — alternative or backup contraception is required during adrafinil use and for at least one month after stopping.[30]
Modafinil also inhibits CYP2C19, potentially increasing blood levels of drugs processed by this enzyme, including phenytoin, diazepam, omeprazole, propranolol, and certain tricyclic antidepressants.[31][20]
Concurrent use with other stimulants (amphetamine, cocaine, methylphenidate) produces additive effects through overlapping dopamine mechanisms, with potential for increased cardiovascular strain. A clinical study found no significant pharmacokinetic interaction between modafinil and methylphenidate specifically.[32]
The combination of modafinil with citalopram (an SSRI) showed increased reinforcing properties in animal models.[33]
No published interaction data exist for combinations with monoamine oxidase inhibitors, lithium, or anticonvulsants. Theoretical concern exists for increased toxicity with MAOI combinations based on mechanism.safety citation needed
Contraindications
Liver impairment is the most significant contraindication specific to adrafinil. Impaired liver function may reduce conversion to modafinil while increasing parent compound exposure.[20]
Known allergy to modafinil or armodafinil is an absolute contraindication, as adrafinil converts to modafinil.
Use in children is contraindicated due to risk of serious skin reactions.[9]
History of psychosis or mania is a relative contraindication due to dopaminergic stimulation.inferred
Heart conditions warrant caution due to potential blood pressure and heart rate elevation.[6]
Hormonal contraceptive use requires mitigation through alternative or backup contraception.[30]
Harm Reduction[edit]
Forms & Identification
Adrafinil circulates primarily as a white crystalline powder sold in capsules or loose powder form through online supplement retailers. Since it is a discontinued pharmaceutical with no current manufacturer, all available product is produced by third-party chemical suppliers without pharmaceutical-grade quality control. Purity can vary significantly between vendors, and mislabeling or substitution with other benzhydryl compounds is possible. Third-party testing through independent laboratories provides the most reliable verification of identity and purity.
Guidelines
- Start with the lowest effective dose and allow a full 2 hours before assessing effects — the prodrug conversion creates a slow onset that does not reflect final intensity
- Use only in the morning or early afternoon to avoid insomnia
- Avoid daily use — chronic dosing increases hepatic burden compared to modafinil
- Request liver enzyme testing before beginning a course of regular use and periodically thereafter
- Stay hydrated and maintain regular meals, as appetite suppression may mask hunger
- Test purchased material through a third-party laboratory when possible
Set & Setting
Adrafinil's delayed onset (1–2 hours) and long duration make timing important. Morning dosing avoids interference with sleep. The effects are subtle compared to traditional stimulants — first-time users sometimes redose prematurely, believing the initial dose was ineffective, leading to excessive stimulation hours later. A calm, productive environment suits the compound's quiet alertness profile.
Aftercare & integration. Adrafinil's long duration means residual stimulation can persist into evening hours. Prioritize sleep recovery: dim lighting, avoid screens, and allow a wind-down period of 2–3 hours before attempting sleep. Eat a full meal if appetite was suppressed during the day. Caffeine should be avoided in the afternoon and evening following adrafinil use.
After regular use, fatigue rebound effect is common for several days. Allow natural sleep–wake cycles to re-establish before resuming any stimulant. If use was motivated by chronic fatigue or cognitive difficulty, consider whether the underlying cause warrants medical evaluation rather than continued self-medication.
Recovery & Support
Physical dependence on adrafinil is rare, but psychological reliance on wakefulness-promoting agents can develop — particularly when use masks underlying sleep disorders, depression, or chronic fatigue. If adrafinil use has become routine to function normally, this pattern warrants honest assessment.
A healthcare provider can evaluate whether an underlying condition is driving the need for cognitive enhancement. For individuals seeking to reduce or stop use, gradual tapering rather than abrupt cessation minimizes fatigue rebound. Support resources include sleep medicine clinics and, where substance use has become compulsive, addiction support services.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Adrafinil emergencies are rare but recognizable.
Signs that require immediate help:
- Chest pain, rapid or irregular heartbeat
- Severe allergic reaction: skin rash, swelling of the face or throat, difficulty breathing
- Uncontrollable involuntary movements, especially of the face or jaw
- Seizure or loss of consciousness
- Severe anxiety or paranoid thinking that does not respond to reassurance
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Keep the person calm, seated, and in a quiet environment
- 3. Do not induce vomiting
- 4. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: name the substance (adrafinil), the amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Adrafinil occupies an unusual position in international drug law: a discontinued pharmaceutical whose active metabolite (modafinil) is a controlled or prescription substance in most jurisdictions, while adrafinil itself remains unscheduled in several major markets. This regulatory asymmetry has facilitated its re-emergence as an over-the-counter nootropic supplement.[4][11]
Both adrafinil and modafinil are prohibited in competitive sport under the World Anti-Doping Agency (WADA) prohibited list, classified under S6 (Stimulants), in-competition only, since 2004.[13][14]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled, unregulated | Not FDA-approved; not a DEA-controlled substance; legal to possess and privately import[4] |
| United Kingdom | Not specifically scheduled | Falls under Psychoactive Substances Act 2016, restricting commercial supply but not personal possession[34] |
| France | Discontinued pharmaceutical | Olmifon marketed 1985–2011; voluntarily withdrawn by Cephalon[2][3] |
| Canada | Unregulated | Legal as research chemical; can be purchased and privately imported[34] |
| Australia | Prescription required | Not freely available over the counter[34] |
| Germany | Available as research chemical | Not approved as pharmaceutical; no prescription required[35] |
| New Zealand | Prescription required | Regulated as prescription medicine[34] |
| WADA (sport) | Prohibited in-competition | S6 Stimulants category since 2004; metabolizes to modafinil (also prohibited)[13][14] |
The Federal Analogue Act (21 U.S.C. § 813) could theoretically apply to adrafinil as a structural and functional analogue of modafinil (Schedule IV), but enforcement under this provision has not been documented. The Act's requirement that a substance be "intended for human consumption" complicates its application to products marketed as "research chemicals" or "dietary supplements".citation needed
references
- [1] ^abcVolkow ND, Fowler JS, Logan J, et al. (2009) Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. — JAMA doi:10.1001/jama.2009.351
- [2]
- [3]
- [4]
- [5]
- [6]